A chessboard with blocks that read MA
Pharma

Neurocrine pays $2.9B for Soleno, its largest M&A deal ever

The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.
Angus Liu Apr 6, 2026 10:30am
Leo Pharma lion

March M&A surge triggers high expectations for 2026

Apr 6, 2026 5:00am
SoonShiong

ImmunityBio responds to FDA warning letter with new protocols

Apr 6, 2026 3:10pm
Doctors on TV series Scrubs

Insulet's Omnipod makes TV debut in 'Scrubs' revival

Apr 6, 2026 2:00pm
Amgen

On-body injected version of Amgen's Tepezza measures up to IV

Apr 6, 2026 9:43am
Fierce Madness 2026 hero image v3

Fierce Madness Drug Name Tournament 2026—The finalists are set

Apr 6, 2026 9:30am
More News

Lilly kicks off anniversary campaign to catch Final Four crowd

Apr 6, 2026 8:38am

Novavax bets on ‘amplification strategy’ with Sanofi, Pfizer deals

Apr 6, 2026 8:37am

An update on the pharma industry’s reshoring effort

Apr 3, 2026 9:41am
Fierce Biotech

Biopharma R&D pipeline shrinks for 1st time in 30 years: report

Apr 3, 2026 8:13am